Core Viewpoint - The recent financial report of Chuangye Huikang (300451) indicates a significant decline in revenue and net profit for Q1 2025 compared to the same period in 2024, raising concerns about the company's financial health and operational efficiency [1][3]. Financial Performance Summary - Total revenue for Q1 2025 was 290 million yuan, a decrease of 22.67% year-on-year from 375 million yuan in Q1 2024 [1]. - The net profit attributable to shareholders for Q1 2025 was -15.64 million yuan, representing a decline of 226.6% compared to a profit of 12.36 million yuan in Q1 2024 [1]. - The gross profit margin improved to 55.12%, an increase of 6.8% year-on-year, while the net profit margin fell to -5.06%, a decrease of 233.34% [1]. - Total receivables accounted for 114.01% of the latest annual revenue, indicating a high level of outstanding payments [1]. Cost and Expense Analysis - Total expenses (sales, management, and financial) amounted to 78.54 million yuan, which is 27.05% of revenue, reflecting a year-on-year increase of 21.54% [1]. - The company reported a significant increase in interest-bearing liabilities, rising by 400.02% to 54.88 million yuan [1]. Market and Operational Insights - The decline in revenue is attributed to the company's client base, primarily public medical institutions, which face strict budget controls and lengthy procurement processes [3]. - The uneven distribution of payment schedules and project acceptance has been influenced by external market conditions and the transition between old and new products [3]. Business Model and Financing - The company has relied heavily on equity financing, with a total financing amount of 2.814 billion yuan and cumulative dividends of 230 million yuan since its listing, resulting in a dividend-to-financing ratio of 0.08 [4].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 6.75 [8][9]. Core Views - The company reported a revenue of RMB 290 million for Q1 2025, a year-on-year decrease of 22.67%, primarily due to the sale of a subsidiary and insufficient orders from delayed tenders [1]. - The company is expected to benefit from the recovery in demand for medical information technology as hospitals increasingly adopt AI solutions [1][3]. - The gross margin for Q1 2025 was 55.12%, an increase of 3.51 percentage points year-on-year, indicating a gradual recovery in profitability despite rising expenses due to declining revenue [2]. - The company is actively integrating AI into its medical services, launching products that cover various clinical applications and expanding its collaborative ecosystem with universities and tech companies [3]. - The company is positioned as a leader in regional health information technology and is expected to benefit from favorable government policies aimed at enhancing healthcare infrastructure [4]. Financial Projections - Revenue projections for the company are estimated at RMB 1.607 billion, RMB 1.821 billion, and RMB 2.071 billion for the years 2025, 2026, and 2027 respectively [5][7]. - The net profit attributable to the parent company is forecasted to recover to RMB 133.21 million in 2025, with further growth expected in subsequent years [7]. - The company’s estimated price-to-sales ratio for 2025 is set at 6.5 times, reflecting confidence in its product rollout and market position [5].

Core Viewpoint - The company reported a significant decline in revenue and incurred losses in the first quarter of 2025 compared to the same period last year, indicating ongoing financial challenges [3]. Financial Performance - The total revenue for the first quarter of 2025 was 290.36 million yuan, a year-on-year decrease of 22.67% [3]. - The net profit attributable to shareholders was a loss of 15.65 million yuan, compared to a profit of 12.36 million yuan in the same period last year [3]. - The net profit after deducting non-recurring gains and losses was a loss of 27.96 million yuan, down from a profit of 9.63 million yuan year-on-year [3]. - The net cash flow from operating activities was -152.17 million yuan, an improvement from -200.64 million yuan in the previous year [3][22]. - Basic and diluted earnings per share were both -0.01 yuan [3]. Profitability Metrics - The weighted average return on equity for the first quarter was -0.35%, a decrease of 0.62 percentage points year-on-year [18]. - The company's capital return rate for the first quarter was -0.38%, down 0.47 percentage points from the previous year [18]. Asset and Liability Changes - As of the end of the first quarter of 2025, total assets were 5.56 billion yuan, slightly down from 5.66 billion yuan year-on-year [2]. - The company's cash and cash equivalents decreased by 29.51% compared to the end of the previous year [32]. - The company’s liabilities showed a decrease in accounts payable by 8.89% and a significant reduction in employee compensation liabilities by 72.7% [35]. Shareholder Changes - New shareholders include the Nuon Active Return Flexible Allocation Mixed Securities Investment Fund and the Guorong Rongsheng Leading Selection Mixed Securities Investment Fund, replacing previous shareholders [43]. - Hong Kong Central Clearing Limited increased its shareholding, while several other shareholders reduced their stakes [43][44]. Valuation Metrics - As of April 25, 2025, the company's price-to-earnings ratio (TTM) was approximately -41.43 times, with a price-to-book ratio (LF) of about 1.89 times and a price-to-sales ratio (TTM) of approximately 6.24 times [2].

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0100 | 0.0100 | -200 | 0.0100 | | 每股净资产（元） | 2.84 | 2.99 | -5.02 | 2.98 | | 每股公积金(元) | 1 | 1.01 | -0.99 | 0.99 | | 每股未分配利润(元) | 0.77 | 0.91 | -15.38 | 0.90 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.9 | 3.75 | -22.67 | 3.48 | | 净利润(亿元) | -0.16 | 0.12 | -233.33 | 0.1 | | 净资产收益率(%) | -0.35 | 0.27 | -229.63 | 0.23 | 本次公司不分配不转赠。 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 49654.6万股，累计占流通股比： 32.52%，较上期变 ...

证券代码：300451 证券简称：创业慧康 公告编号: 2025-025 创业慧康科技股份有限公司 关于 2025 年第一季度计提信用减值准备和资产减值准备 的公告 二、本次计提信用减值准备及资产减值准备的确认标准及计提方法 公司以单项金融工具或金融工具组合为基础评估预期信用风险和计量预期 信用损失。当以金融工具组合为基础时，公司以共同风险特征为依据，将金融工 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）根据《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》《企业会计准则》以 及公司相关会计政策的规定，在 2025 年第一季度计提了信用减值损失及资产减 值损失，现将具体情况公告如下： 一、本次计提信用减值准备和资产减值准备情况概述 1、本次计提信用减值准备和资产减值准备的原因 根据《企业会计准则》《深圳证券交易所创业板股票上市规则》等相关规定 的要求，为真实准确地反映公司截至 2025 年 3 月 31 日的财务状况和经营成果， 公司对截至 2025 年 3 月 31 日的各类资产进行了减值 ...

Financial Performance - The company's revenue for Q1 2025 was ¥290,357,981.79, a decrease of 22.67% compared to ¥375,491,442.27 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥15,647,403.70, representing a decline of 226.60% from a profit of ¥12,359,662.56 in the previous year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥27,959,264.39, a decrease of 389.48% compared to a profit of ¥9,658,288.80 last year[4]. - The total amount of sales and management expenses decreased by 15.70% year-on-year, while net cash flow from operating activities increased by 24.16% year-on-year[14]. - Total operating revenue for the current period was CNY 290,357,981.79, a decrease of 22.7% compared to CNY 375,491,442.27 in the previous period[20]. - The net profit for the current period was a loss of CNY 14,702,055.36, compared to a profit of CNY 14,258,715.78 in the previous period[20]. - The total comprehensive income attributable to the parent company was -15,647,403.70, compared to 12,359,640.67 in the previous period[21]. - Basic and diluted earnings per share were both -0.01, compared to 0.01 in the previous period[21]. Cash Flow and Assets - The net cash flow from operating activities was -¥152,166,660.54, an improvement of 24.16% from -¥200,644,939.83 in the previous year[4]. - The company's total assets decreased to CNY 5,564,740,193.08 from CNY 5,668,132,706.72, a decline of 1.8%[19]. - Current assets totaled CNY 3,007,557,226.42, down from CNY 3,075,922,035.12, indicating a decrease of 2.2%[19]. - The total liabilities decreased to CNY 1,102,949,579.87 from CNY 1,194,672,281.56, a reduction of 7.7%[19]. - The company's cash and cash equivalents decreased to CNY 718,220,351.12 from CNY 1,018,894,565.64, a decline of 29.5%[19]. - The cash received from the sale of goods and services was 246,234,254.96, slightly up from 246,047,168.37 in the previous period[23]. - The total cash outflow from operating activities was 425,154,234.18, down from 470,935,394.21 in the previous period[24]. - The cash and cash equivalents at the end of the period were 716,252,709.50, down from 802,849,099.37 at the end of the previous period[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 82,383[11]. - The largest shareholder, Ge Hang, holds 13.24% of shares, totaling 205,074,982 shares, with 40,000,151 shares frozen[11]. - The total number of restricted shares at the end of the reporting period is 22,430,922, with no shares released during the current period[13]. Investments and Development - The company reported a significant increase of 1135.01% in trading financial assets due to increased purchases of financial products[7]. - Development expenditures grew by 595.40% due to increased investment in new product development[7]. - Financial expenses increased by 90.31% compared to the previous year, primarily due to the expiration of large time deposits[7]. - Research and development expenses increased to CNY 79,270,029.19 from CNY 68,350,032.14, an increase of 16.5%[20]. Government Support and Market Position - The company received government subsidies amounting to ¥9,112,157.03 during the reporting period[5]. - The company is positioned to benefit from policy incentives and market expansion opportunities in the healthcare information technology sector, particularly in county-level medical community information system construction[14]. Product Development and Recognition - The company signed 8 new orders worth over 10 million during the reporting period, indicating stable demand in the healthcare information technology sector[14]. - The company has integrated its DeepSeek model with medical scenarios and launched the BsoftGPT·DeepSeek medical industry all-in-one machine, covering numerous medical applications[15]. - The "Smart Diagnosis Generation Algorithm" (BsoftGPT) was recognized in the 2024 Zhejiang Province "Smart Products" list, marking a significant technological achievement[15]. - The company aims to optimize medical resource allocation through deep integration of big data analysis and machine learning, enhancing diagnostic support for doctors and improving patient care pathways[15].

Core Viewpoint - The company, Chuangyue Huikang, has experienced a decline in revenue and net profit in its latest financial report, indicating potential challenges in its business operations while maintaining a relatively stable market presence with a modest increase in shareholder numbers [3][4]. Company Overview - Chuangyue Huikang focuses on the construction, research, and innovative services of healthcare information technology, offering a range of products including hospital information software, public health software, and various cloud platforms [2]. - The company has received multiple honors, such as being recognized as a "China Software Integrity Demonstration Enterprise" and a "Top 100 Digital Economy Enterprise in Hangzhou" [2]. Financial Performance - In the 2024 annual report, the company reported a revenue of 1.423 billion yuan, a year-on-year decrease of 11.96%, and a net loss of approximately 173.52 million yuan, reflecting a significant decline of 572.96% compared to the previous year [3]. - The gross profit margin stood at 45.18%, indicating the company's ability to maintain a relatively high margin despite the drop in revenue [3]. Market Position - As of April 25, the company's stock closed at 5.39 yuan, with a market capitalization of 8.35 billion yuan and a price-to-book ratio of 1.89 [1]. - The number of shareholders increased to 82,383, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].

Core Viewpoint - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by seven government departments aims to enhance the digital transformation across the entire pharmaceutical industry chain, focusing on the deep application of artificial intelligence technology and the cultivation of excellent enterprises [1][3]. Group 1: Market Impact - Following the announcement, the pharmaceutical digitalization sector in the A-share market saw a collective rise, with notable increases such as 13.16% for Sichuang Medical [2][1]. - The digital transformation plan is expected to create significant opportunities for the pharmaceutical industry, effectively equipping it with a "digital brain" to enhance efficiency and reduce costs [6][7]. Group 2: Development Goals - The plan outlines two key stages: by 2027, significant progress in digital transformation should be achieved, and by 2030, large-scale pharmaceutical enterprises should have fully realized digital transformation [3][4]. - Specific targets include the development of over 30 digital technology standards and the establishment of more than 100 exemplary application scenarios in the pharmaceutical industry [4][5]. Group 3: Key Tasks - The plan identifies four major tasks: empowering with digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation [5][6]. Group 4: Market Growth Potential - The digital healthcare market in China is projected to exceed 1.2 trillion yuan by the end of 2024, with a compound annual growth rate of 24.5% [8]. - By 2025, the digital healthcare market is expected to surpass 1.8 trillion yuan, and by 2030, it could reach 2.5 trillion yuan, indicating a significant market opportunity driven by policy, technology, and demand [9]. Group 5: Company Innovations - Companies like Hengrui Medicine and Fosun Pharma are collaborating with AI platforms to enhance the efficiency of innovative drug development [11]. - Other firms, such as WuXi AppTec and Chengdu XianDao, are integrating AI into their research processes to improve precision and efficiency in drug development [10][11].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance in the near term [3][5]. Core Insights - The company reported a revenue of 1.423 billion yuan for 2024, a decrease of 11.96% year-on-year, and a net profit attributable to shareholders of -174 million yuan [1]. - The gross margin for the year was 45.18%, down by 1.8 percentage points compared to the previous year [1]. - In Q4 2024, the company achieved a revenue of 254 million yuan, reflecting a significant decline of 44.65% year-on-year, with a net profit of -226 million yuan [1]. - The company has expanded its business in smart healthcare and public health, securing 31 new software orders worth a total of 580 million yuan [1]. - The HI-HIS new product has been successfully implemented in several key projects across regions such as South China, Central China, and Northwest China, with a 41% year-on-year increase in new orders [1][2]. Financial Summary - The financial summary indicates a projected revenue growth for the company, with estimates of 1.599 billion yuan in 2025, 1.857 billion yuan in 2026, and 2.153 billion yuan in 2027, reflecting growth rates of 12.39%, 16.14%, and 15.95% respectively [4][13]. - The net profit is expected to recover to 9 million yuan in 2025, 65 million yuan in 2026, and 136 million yuan in 2027, showing significant growth from the negative profit in 2024 [4][13]. - The report highlights a projected gross margin improvement, with estimates of 45.6% in 2025, 46.3% in 2026, and 46.9% in 2027 [4][13].

Core Viewpoint - The company, Chuangye Huikang, has experienced a significant decline in both revenue and net profit for the year 2024, indicating challenges in its operational performance and market conditions [3]. Stockholder Changes - As of March 31, 2025, the number of shareholders increased to 82,400, up by 28,300 from December 31, 2024, representing a growth rate of 52.45%. The average number of shares held per shareholder decreased from 28,700 to 18,800, with an average holding value of 115,500 yuan [2][6]. Performance Disclosure - The company's main revenue for 2024 was 1.423 billion yuan, a year-on-year decrease of 11.96%. The net profit attributable to shareholders was -174 million yuan, down 572.96% year-on-year. The non-recurring net profit was -192 million yuan, a decline of 664.96%. In Q4 2024, the single-quarter main revenue was 254 million yuan, down 44.65%, with a net profit of -226 million yuan, a decrease of 313.73% [3][6]. Institutional Research Insights - During an investor communication meeting on April 14, the company explained that the decline in revenue was primarily due to strict budget controls and centralized procurement processes followed by public medical institutions, leading to longer procurement cycles. The company is committed to advancing its "Huikang Cloud" strategy, focusing on product quality and technological ecosystem development to meet user demands [4]. - The company launched the smart medical assistant MedCopilot in 2024, which integrates medical models and clinical data to support physicians with intelligent diagnostic assistance and electronic medical record management. This product has been implemented in various medical institutions [5][6]. - For 2025, the company plans to enhance its core business competitiveness by optimizing the technical architecture of its core systems and establishing standardized project implementation processes and quality control systems [5].